Valiant Organics Board Approves Q1 FY27 Results, Reappoints MD, and Approves Office Shift
Valiant Organics reported Q1 FY27 results. The Board reappointed Shri Sathiababu K. Kallada as MD for three years from May 24, 2027. The company also approved shifting its registered office to Tarapur, Palghar, subject to shareholder approval.
The re-appointment of the Managing Director and the shifting of the registered office are significant corporate actions that could impact operations and governance, warranting a medium impact assessment.
The announcement includes financial results and key management changes, but the overall sentiment is neutral as it reports routine corporate actions and financial performance without significant positive or negative triggers.
Valiant Organics Limited announced the outcome of its Board Meeting held on August 12, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
In a significant development, the Board also approved the re-appointment of Shri Sathiababu K. Kallada as the Managing Director for a term of three years, effective from May 24, 2027, to May 23, 2030. This re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. Shri Sathiababu K. Kallada, with over 38 years of experience in the chemical industry, is not related to any other director of the company.
Furthermore, the Board approved the shifting of the Company's Registered Office from Mulund West, Mumbai, to Plot No. M-7, MIDC, Tarapur, Boisar, Palghar, Maharashtra. This relocation requires shareholder approval at the ensuing Annual General Meeting and involves a change in jurisdiction. The company also informed that its Corporate Office is now located at 701-A, Tower-B, Embassy 247 Park, Vikhroli (West), Mumbai.
The Board meeting commenced at 12:35 PM IST and concluded at 03:50 PM IST.
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.